daftar pustaka - diponegoro universityeprints.undip.ac.id/50496/8/eka_aryani... · daftar pustaka...
Post on 08-Feb-2018
213 Views
Preview:
TRANSCRIPT
80
DAFTAR PUSTAKA
1. Creager M, Libby P. Peripheral Arterial Disease In: Mann DL, Zipes DP,
Libby P, Bonow RO, editors. Braunwald’s Heart Disease : A Textbook of
Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier Saunders; 2015.
1312 p.
2. Antono D, Hamonangani R. Penyakit Arteri Perifer. In: Setiati S, editor.
Buku Ajar Ilmu Penyakit Dalam. 1st ed. Jakarta: InternaPublishing; 2014.
p. 1516–26.
3. Rhee SY, Kim YS. Peripheral Arterial Disease in Patients with Type 2
Diabetes Mellitus. 2015;283–90.
4. Coffman JD, Eberhardt RT. Peripheral Arterial Disease, Diagnosis and
Treatment. New York: Springer Seienee&Business Media; 2003.1-34p.
5. Rooke TW, Hirsch a. T, Misra S, Sidawy a. N, Beckman J a., Findeiss LK,
et al. 2011 ACCF/AHA Focused Update of the Guideline for the
Management of Patients With Peripheral Artery Disease. Circulation.
Elsevier Inc.; 2011;58(19):2020–45.
6. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott
MM, et al. Comparison of global estimates of prevalence and risk factors
for peripheral artery disease in 2000 and 2010: a systematic review and
analysis. Lancet. Elsevier Ltd; 2013;382(9901):1329–40.
7. Selvin E. Prevalence of and Risk Factors for Peripheral Arterial Disease in
the United States: Results From the National Health and Nutrition
Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.
8. Fowkes FGR, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of
atherothrombosis in 8891 patients with or at risk of vascular disease:
Results of the international AGATHA study. Eur Heart J.
2006;27(15):1861–7.
9. Rhee SY, H G, ZM L, SW-K C, S W, P P. Multi-country study on the
prevalence and clinical features of peripheral arterial disease in Asian type
2 diabetes patients at high risk of atherosclerosis. Diabetes Res Clin Pract.
2007;76(1):82–92.
10. American Diabetes Association. Epidemiology and Impact of Peripheral
Arterial Disease in People with Diabetes. Diabetes Care.
2003;26(12):3333–41.
81
11. American Heart Association. What is peripheral vascular disease? In
American Heart Association; 2012.
12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL,
et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients
With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and
Abdominal Aortic). Circulation. 2006;113(11):e463–5.
13. Norgren L, Hiatt WR, Dormandy J a., Nehler MR, Harris K a., Fowkes
FGR, et al. Inter-Society Consensus for the management of peripheral
arterial disease (TASC II). Int Angiol. 2007;26(2):82–157.
14. F Brian Boudi M. Coronary Artery Atherosclerosis Treatment &
Management. Medscape. 2016; [cited 2016 Jun 17]
15. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J
Am Coll Cardiol. 2006;47(5):921–9.
16. The Japan Diabetes Society. Evidence-based Practice Guideline for the
Treatment for Diabetes in Japan 2013. Diabet Med. 2013;1–3.
17. Ilmiah Populer [Internet]. [cited 2016 Jan 26]. Available from:
http://www.pdpersi.co.id/content/popular_science.php?psid=30
18. Dinas Kesehatan Jateng. Daftar Tabel Profil Kesehatan Provinsi Jawa
Tengah. Semarang: Dinkes Jateng; 2008. 38 p.
19. Huh JH, Choi E, Lim JS, Lee MY, Chung CH, Shin JY. Serum cystatin C
levels are associated with asymptomatic peripheral arterial disease in type 2
diabetes mellitus patients without overt nephropathy. Diabetes Res Clin
Pract. Elsevier Ireland Ltd; 2015;108(2):258–64.
20. Rahman A. Faktor – Faktor Risiko Mayor Aterosklerosis pada Berbagai
Penyakit Aterosklerosis di RSUP Dr. Kariadi Semarang. Diponegoro
University; 2012.
21. Tomeleri CM, Ronque ER, Silva DR, Cardoso Junior CG, Fernandes R a,
Teixeira DC, et al. Prevalence of dyslipidemia in adolescents: comparison
between definitions. Rev Port Cardiol. Sociedade Portuguesa de
Cardiologia; 2015;34(2):103–9.
22. Bittner V. Perspectives on dyslipidemia and coronary heart disease in
women: an update. Curr Opin Cardiol. 2006;21(6):602–7.
23. Fakhrzadeh H, Tabatabaei-malazy O. Dyslipidemia and Cardiovascular
Disease. Endocrinol Metab Res Cent Tehran Univ Med Sci. 2008;
82
24. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar
(RISKESDAS) 2007. Lap Nas 2007. 2008;1–384.
25. Rinandyta SA. Perbedaan Kadar LDL pada Penderita Diabetes Melitus
Tipe 2 dengan Hipertensi dan Tanpa Hipertensi di RSUD Dr. Moewardi.
Universitas Muhammadiyah Surakarta; 2012.
26. Ilminovia F. Hubungan antara Status Diabetes Melitus dengan Status
Penyakit Arteri Perifer (PAP) pada Pasien Hipertensi In Abstract Book
ESC 26th. European student congress; 2015.
27. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J,
editors. Harrison’s Principles of Internal Medicine. 18th ed. New York: Mc
Graw Hill; 2012. 2066 p.
28. Agrawal K, Eberhardt RT. Contemporary Medical Management of
Peripheral Arterial Disease. Cardiol Clin. Elsevier Inc; 2015;33(1):111–37.
29. Runge MS, Greganti MA. Netter’s Internal Medicine. 2nd ed. Philadelphia:
Saunders Elsevier; 2009. 213 p.
30. McDermott, M M, McGrae. Lower Extremity Manifestations of Peripheral
Artery Disease. Am Hear Assoc J. 2015;115:1540–50.
31. Lozano FS, González-Porras JR, March JR, Lobos JM, Carrasco E, Ros E.
Diabetes mellitus and intermittent claudication: a cross-sectional study of
920 claudicants. Diabetol Metab Syndr. 2014;6:21.
32. Hallett Jr JW. Peripheral Arterial Disease. Merck Manuals. 2008;169–73.
33. Bordeaux LM, Reich LM, Hirsch AT. The Epidemiology and Natural.
Springer J. 2003;(Ic):21–35.
34. Baker. Smoking and Peripheral Arterial Disease ( PAD ). ASH Research
Report Smoking and Peripheral Arterial Disease. 2014;
35. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, Collet
J-P, et al. ESC Guidelines on the diagnosis and treatment of peripheral
artery diseases: Document covering atherosclerotic disease of extracranial
carotid and vertebral, mesenteric, renal, upper and lower extremity arteries
* The Task Force on the Diagnosis and Treat. Eur Heart J.
2011;32(22):2851–906.
36. Olin JW, Sealove B a. Peripheral artery disease: current insight into the
disease and its diagnosis and management. Mayo Clin Proc.
2010;85(7):678–92.
83
37. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG. Peripheral
arterial disease detection, awarness and treatment in primary care. JAMA.
2001;286(11):1317–24.
38. Age AT. Peripheral Arterial Disease in the Legs. In: CdcGov. p. 4–5.
39. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL.
ACC/AHA 2005 practice guidelines for the Management of Patients with
Peripheral Arterial Disease (lower extremity, renal, mesenteric, and
abdominal aortic): a collaborative report from the American Association for
Vascular Surgery/Society for Vascular Sur. Circulation. 2006;113(11):463–
654.
40. Suyono S. Diabetes Melitus. In: Setiati S, editor. Buku Ajar Ilmu Penyakit
Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2315–418.
41. American Diabetes Association. Classification and Diagnosis of Diabetes.
Diabetes Care. 2015;38(Supplement_1):S8–16.
42. Hirsch a T, Hiatt WR. PAD awareness, risk, and treatment: new resources
for survival--the USA PARTNERS program. Vasc Med. 2001;6(3
Suppl):9–12.
43. Joshua A, Beckman, MD M, Mark A. Creager M, Peter Libby M. Diabetes
and Atherosclerosis Epidemiologi, Pathophysiology, and Management.
JAMA. 2002;(287):2570–81.
44. Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S, et al. Muscle
Perfusion by Capillary Recruitment. 2001;50
45. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function.
European Heart Journal. 2012;33(7):829–37.
46. Hua L, Hongliang L, Yige B, Xiangxun Z, Yerong Y. Free Fatty Acids
Induce Endothelial Dysfunction and Activate Protein Kinase C and Nuclear
Factor-κB Pathway in Rat Aorta. Int J Cardiol. 152(2):218–24.
47. Erwinanto, Santoso A, Putranto JNE, Tedjasukmana P, Suryawan R, Rifqi
S, et al. Pedoman tatalaksana dislipidemia. 1st ed. Perhimpunan Dokter
Spesialis Kardiovaskular Indonesia; 2013.1-7p.
48. PERKENI. Konsensus Pengelolaan Dislipidemia di Indonesia. Jakarta:
Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran UI; 2012.15-
21p.
84
49. Fodor G. Primary prevention of CVD: Treating dyslipidemia. Am Fam
Physician. 2011;83(10):1207–8.
50. Adam JM. Dislipidemia. In: Setiati S, editor. Buku Ajar Ilmu Penyakit
Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2549–68.
51. Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei B, et al.
Metformin beyond diabetes: Pleiotropic benefits of metformin in
attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):1–12.
52. Jamkhande PG, Chandak PG, Dhawale SC, Barde SR, Tidke PS, Sakhare
RS. Therapeutic approaches to drug targets in atherosclerosis. Saudi Pharm
J SPJ Off Publ Saudi Pharm Soc. King Saud University; 2014;22(3):179–
90.
53. Elizabeth Klodas M. High Blood Pressure and Atherosclerosis. WebMD.
2016; [cited 2016 Jun 17]
54. Aboyans V, Criqui MH, Abraham P, Allison M a., Creager M a., Diehm C,
et al. Measurement and Interpretation of the Ankle-Brachial Index: A
Scientific Statement From the American Heart Association. Circulation.
2012;126(24):2890–909.
55. Mahameed A Al. Peripheral Arterial Disease. Cleve Clin J Med. 2009;
56. Bonham P, Cappuccio M, Hulsey T, Michel Y, Kelechi T, Jenkins C. Are
Ankle and Toe Brachial Indices (ABI-TBI) Obtained by a Pocket Doppler
Interchangeable With Those Obtained by Standard Laboratory Equipment?
J Wound, Ostomy Cont Nurs. 2007;34(1):35–44.
57. Carmo G a L, Mandil a, Nascimento BR, Arantes BD, Bittencourt JC,
Falqueto EB, et al. Can we measure the ankle-brachial index using only a
stethoscope? A pilot study. Fam Pract. 2009;26(1):22–6.
58. WOCN Wound Committee. Ankle Brachial Index. J Wound, Ostomy Cont
Nurs. 2012;39(April):S21–9.
59. Inada A, Weir GC, Bonner-Weir S. Induced ICER I?? down-regulates
cyclin a expression and cell proliferation in insulin-producing ?? cells.
Biochem Biophys Res Commun. 2005;329(3):925–9.
60. Yogiantoro M. Hipertensi Esensial. Buku Ajar Ilmu Penyakit Dalam Jilid
1. IV. Jakarta: FKUI; 2006. 610-14 p.
61. F Brian Boudi M. Treatment of Low HDL levels and High Triglyceride
levels in Patients With Diabetes. Medscape. 2016;[cited 2016 Jun 17]
85
62. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial
disease in the United States: Results from the National Health and Nutrition
Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.
63. Pepine CJ, Handberg EM. The vascular biology of hypertension and
atherosclerosis and intervention with calcium antagonists and angiotensin-
converting enzyme inhibitors. Clin Cardiol. 2001;24(11 Suppl):V1–5.
86
Lampiran 1. Informed Consent (Persetujuan Pasien)
JUDUL PENELITIAN : Hubungan antara Dislipidemia dengan Derajat
Keparahan Penyakit Arteri Perifer (PAP) pada
Pasien Diabetes Melitus Tipe 2 Terkontrol Sedang.
INSTANSI PELAKSANA : Bagian Ilmu Penyakit Dalam FK Undip -
Mahasiswa Program Studi Strata-1 Kedokteran
Umum Fakultas Kedokteran Universitas
Diponegoro
PERSETUJUAN SETELAH PENJELASAN
(INFORMED CONSENT) Yth Bapak/Ibu …………………………………..
Nama saya Eka Aryani, saya mahasiswa Program Studi S1 Ilmu
Pendidikan Dokter Fakultas Kedokteran UNDIP. Saya melakukan penelitian
dengan judul “Hubungan antara Dislipidemia dengan Derajat Keparahan Penyakit
Arteri Perifer (PAP) pada Pasien Diabetes Melitus Tipe 2 Terkontrol Sedang”.
Tujuan dari penelitian ini adalah untuk mengetahui hubungan antara dislipidemia
dengan derajat keparahan penyakit arteri perifer (PAP) pada pasien DM tipe 2
terkontrol sedang. Dislipidemia adalah kelainan metabolisme lipid (lemak darah)
dimana terjadi peningkatan maupun penurunan komponen lipid seperti kolesterol
total, kolesterol LDL (Low Density Lipoprotein), TG (trigliserida), serta
menurunnya kolesterol HDL (High Density Lipoprotein) dalam darah. Penyakit
arteri perifer adalah gangguan suplai darah ke ekstremitas atas atau bawah
(tungkai atau lengan) karena obstruksi atau sumbatan sehingga timbul gejala
seperti rasa nyeri pada ekstremitas tersebut(klaudikasio intermiten). Bapak/Ibu
87
terpilih sebagai peserta penelitian ini. Apabila Bapak/Ibu setuju untuk menjadi
peserta penelitian maka ada beberapa hal yang akan Bapak/Ibu alami, yaitu:
- Pengambilan informasi nama, umur, jenis kelamin, status merokok, status
hipertensi dan keluhan yang dirasakan melalui wawancara
- Diukur tekanan darah pada kedua kaki dan kedua lengan pada saat istirahat
- Dan bila diperlukan, akan diukur tekanan darah pada kaki setelah berolah
raga naik-turun bangku selama 4-5 menit atau berjalan selama 6 menit atau
dorsofleksi plantarfleksi selama 6 menit.
Keuntungan bagi Bapak/Ibu yang bersangkutan ikut dalam penelitian ini
adalah mendapat fasilitas pendeteksian Penyakit Arteri Perifer (PAP) serta
mengetahui derajat PAP yang diderita apabila terdeteksi. Dengan dilakukanya
pendeteksian ini, kita dapat mengetahui apakah terdapat sumbatan pembuluh
darah pada lengan atau kaki Bapak/Ibu. Bapak/Ibu juga akan diberi pemahaman
mengenai PAP. Saya menjamin bahwa penelitian ini tidak akan menimbulkan
efek yang merugikan pada Bapak/Ibu. Dalam penelitian ini tidak ada intervensi
dalam bentuk apapun terhadap Bapak/ Ibu. Setiap data pemeriksaan dan penelitian
dijamin kerahasiaannya dengan tidak mencantumkan identitas subyek. Sebagai
peserta penelitian keikutsertaan ini bersifat sukarela dan tidak dikenakan biaya
penelitian.
Penanggung jawab penelitian:
Eka Aryani
085642702444
Sudah mendengar dan memahami penjelasan penelitian, dengan ini saya
menyatakan
SETUJU / TIDAK SETUJU
untuk ikut sebagai subyek/sampel penelitian ini.
Tegal, …………………….2016
Saksi
Nama Terang : Nama Terang :
Alamat : Alamat :
88
Lampiran 2
DAFTAR TILIK PENELUSURAN REKAM MEDIK
No Keterangan
Nama
Jenis Kelamin
Umur
Alamat
No HP
Kontrol teratur/tidak
Status merokok ya/ tidak
DM
Status glikemik (HbA1c):
Kadar gula darah terakhir
GDS:
GDP:
Lamanya DM:
Obat yang diminum:
Dislipidemia ya/ tidak
TC:
LDL:
HDL:
TG:
Lamanya dislipidemia:
Obat yang diminum:
Hipertensi
Tekanan darah terakhir:
Obat yang diminum:
89
Lampiran 3
LEMBAR PENGUMPULAN DATA
ANKLE-BRACHIAL INDEX (ABI)
Tanggal Pemeriksaan:
Nama Pasien: Umur:
Catatan:
Apakah ada aktivitas berat yang baru
saja dilakukan/ konsumsi kafein/
alkohol terakhir
Jenis Kelamin:
ABI saat istirahat
Kanan Pengukuran Rata-
rata
Kiri Pengukuran Rata-
rata I II I II
Brachialis Brachialis
Tibialis
Posterior
Tibialis
Posterior
Dorsalis
Pedis
Dorsalis
Pedis
ABI kanan = rata − rata tertinggi tekanan sistolik kaki kanan DP atau TP
rata − rata tertinggi tekanan sistolik lengan kanan atau kiri
ABI kiri = rata − rata tertinggi tekanan sistolik kaki kiri DP atau TP
rata − rata tertinggi tekanan sistolik lengan (kanan atau kiri)
Nilai ABI saat istirahat =
90
ABI setelah exercise
(Diakukan apabila nilai ABI saat istirahat normal namun terdapat gejala
klaudikasio)
Lamanya exercise =
Nilai tekanan sistolik kaki setelah exercise =
Nilai ABI setelah exercise =
Kelengkapan Data
Status Merokok :
Lamanya DM :
Lamanya Dislipidemia
Minum obat hipertensi teratur atau tidak :
Minum obat diabetes teratur atau tidak :
Minum obat dislipidemia teratur atau tidak :
91
Lampiran 4. Izin Penelitian
92
93
Lampiran 5. Dokumentasi Penelitian
94
95
Lampiran 6. Biodata Mahasiswa
Identitas
Nama Lengkap : Eka Aryani
Jenis Kelamin : Perempuan
Program Studi : Pendidikan Dokter
NIM : 22010112110093
Tempat, tanggal lahir : Tegal, 14 Februari 1995
E-mail : eka.aryani1402@gmail.com
Nomor telepon/HP : 085642702444
Riwayat Pendidikan Formal
SD SMP SMA S1
Nama Institusi SDN
Margadana 3
Kota Tegal
SMPN 18
Kota Tegal
SMAN 1 Kota
Tegal
Pendidikan
Dokter
Fakultas
Kedokteran
UNDIP
Tahun masuk-
lulus
2000-2006 2006-2009 2009-2012 2012
Organisasi yang Pernah Diikuti:
Lembaga Tahun
Divisi Pengembangan Mahasiswa
Kelompok Studi Mahasiswa FK
UNDIP
2013-2014
Bidang Riset HIMA KU UNDIP 2012-2014
Kelompok Ilmiah Remaja SMAN 1
Kota Tegal
2010-2012
Pengalaman Mengikuti Lomba Karya Ilmiah
Potensi Teng-teng Natto sebagai Alternatif Terapi Aterosklerosis, LKTI-GT Mini
Scientific Fair 2014, Peserta Terbaik.
96
Lampiran 7. Hasil SPSS
Frequencies
Frequency Table
Status Dislipidemia
Frequency Percent Valid Percent Cumulative
Percent
Valid
ya 21 70,0 70,0 70,0
tidak 9 30,0 30,0 100,0
Total 30 100,0 100,0
Jenis kelamin
Frequency Percent Valid Percent Cumulative
Percent
Valid
Laki-laki 17 56,7 56,7 56,7
Perempuan 13 43,3 43,3 100,0
Total 30 100,0 100,0
Usia
N Valid 30
Missing 0
Mean 59,17
Median 58,50
Std. Deviation 7,250
Minimum 46
Maximum 71
Usia
Frequency Percent Valid Percent Cumulative
Percent
Valid
46 2 6,7 6,7 6,7
50 2 6,7 6,7 13,3
51 1 3,3 3,3 16,7
52 1 3,3 3,3 20,0
53 2 6,7 6,7 26,7
54 2 6,7 6,7 33,3
55 2 6,7 6,7 40,0
57 1 3,3 3,3 43,3
58 2 6,7 6,7 50,0
59 1 3,3 3,3 53,3
62 1 3,3 3,3 56,7
97
64 3 10,0 10,0 66,7
65 2 6,7 6,7 73,3
66 2 6,7 6,7 80,0
67 3 10,0 10,0 90,0
68 2 6,7 6,7 96,7
71 1 3,3 3,3 100,0
Total 30 100,0 100,0
Status merokok
Frequency Percent Valid Percent Cumulative
Percent
Valid
Ya 6 20,0 20,0 20,0
pasif 5 16,7 16,7 36,7
mantan 3 10,0 10,0 46,7
tidak 16 53,3 53,3 100,0
Total 30 100,0 100,0
Hipertensi
Frequency Percent Valid Percent Cumulative
Percent
Valid
Ya 13 43,3 43,3 43,3
Tidak 17 56,7 56,7 100,0
Total 30 100,0 100,0
Penyakit atherosclerosis lain
Frequency Percent Valid Percent Cumulative
Percent
Valid
Ya 7 23,3 23,3 23,3
Tidak 23 76,7 76,7 100,0
Total 30 100,0 100,0
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Status Dislipidemia * Status
PAP
30 100,0% 0 0,0% 30 100,0%
98
Status Dislipidemia * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Status Dislipidemia
ya
Count 12 9 21
Expected Count 8,4 12,6 21,0
% within Status PAP 100,0% 50,0% 70,0%
% of Total 40,0% 30,0% 70,0%
tidak
Count 0 9 9
Expected Count 3,6 5,4 9,0
% within Status PAP 0,0% 50,0% 30,0%
% of Total 0,0% 30,0% 30,0%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Exact Sig. (2-
sided)
Exact Sig. (1-
sided)
Pearson Chi-Square 8,571a 1 ,003
Continuity Correctionb 6,356 1 ,012
Likelihood Ratio 11,699 1 ,001
Fisher's Exact Test ,004 ,003
Linear-by-Linear Association 8,286 1 ,004
N of Valid Cases 30
a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 3,60.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort Status PAP =
Tidak
,429 ,262 ,702
N of Valid Cases 30
99
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Kolesterol total Ya 12 212,00 45,798 13,221
Tidak 9 164,33 34,077 11,359
Independent Samples Test
Levene's
Test for
Equality of
Variances
t-test for Equality of Means
F Sig. t df Sig. (2-
tailed)
Mean
Differenc
e
Std.
Error
Differenc
e
95% Confidence
Interval of the
Difference
Lower Upper
Kolester
ol total
Equal variances
assumed
1,62
2
,218 2,61
9
19 ,017 47,667 18,199 9,577 85,757
Equal variances
not assumed
2,73
5
18,999 ,013 47,667 17,430 11,184 84,149
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
LDL Ya 12 136,83 31,007 8,951
Tidak 9 104,44 30,566 10,189
Independent Samples Test
Levene's Test for
Equality of
Variances
t-test for Equality of Means
F Sig. t df Sig. (2-
tailed)
Mean
Differenc
e
Std.
Error
Differenc
e
95% Confidence
Interval of the
Difference
Lower Upper
LDL
Equal variances
assumed
,042 ,840 2,383 19 ,028 32,389 13,591 3,942 60,836
Equal variances
not assumed
2,388 17,52
3
,028 32,389 13,562 3,841 60,937
100
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
HDL Ya 12 25,58 9,549 2,756
Tidak 9 33,67 5,074 1,691
NPar Tests
Mann-Whitney Test
Ranks
Status PAP N Mean Rank Sum of Ranks
Trigliserida
Ya 12 13,42 161,00
Tidak 9 7,78 70,00
Total 21
Test Statisticsa
Trigliserida
Mann-Whitney U 25,000
Wilcoxon W 70,000
Z -2,061
Asymp. Sig. (2-tailed) ,039
Exact Sig. [2*(1-tailed Sig.)] ,041b
a. Grouping Variable: Status PAP
b. Not corrected for ties.
Independent Samples Test
Levene's Test for
Equality of Variances
t-test for Equality of Means
F Sig. t df Sig. (2-
tailed)
Mean
Differenc
e
Std. Error
Differenc
e
95% Confidence
Interval of the
Difference
Lower Upper
HDL
Equal variances
assumed
4,985 ,038 -
2,298
19 ,033 -8,083 3,517 -15,445 -,721
Equal variances
not assumed
-
2,499
17,44
3
,023 -8,083 3,234 -14,893 -1,273
101
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
jumlah dislipidemia * Status PAP 21 100,0% 0 0,0% 21 100,0%
jumlah dislipidemia * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
jumlah dislipidemia
1 komponen
Count 0 6 6
Expected Count 3,4 2,6 6,0
% within Status PAP 0,0% 66,7% 28,6%
% of Total 0,0% 28,6% 28,6%
2 komponen
Count 9 3 12
Expected Count 6,9 5,1 12,0
% within Status PAP 75,0% 33,3% 57,1%
% of Total 42,9% 14,3% 57,1%
3 komponen
Count 2 0 2
Expected Count 1,1 ,9 2,0
% within Status PAP 16,7% 0,0% 9,5%
% of Total 9,5% 0,0% 9,5%
4 komponen
Count 1 0 1
Expected Count ,6 ,4 1,0
% within Status PAP 8,3% 0,0% 4,8%
% of Total 4,8% 0,0% 4,8%
Total
Count 12 9 21
Expected Count 12,0 9,0 21,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 57,1% 42,9% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 11,813a 3 ,008
Likelihood Ratio 15,186 3 ,002
Linear-by-Linear Association 8,710 1 ,003
N of Valid Cases 21
a. 6 cells (75,0%) have expected count less than 5. The minimum expected count is
,43.
102
Frequencies
jenis komponen
Frequency Percent Valid Percent Cumulative
Percent
Valid
HDL 4 19,0 19,0 19,0
TG 2 9,5 9,5 28,6
TC HDL 1 4,8 4,8 33,3
HDL TG 10 47,6 47,6 81,0
LDL HDL 1 4,8 4,8 85,7
TC LDL HDL 2 9,5 9,5 95,2
TC LDL HDL TG 1 4,8 4,8 100,0
Total 21 100,0 100,0
NPar Tests
Descriptive Statistics
N Mean Std.
Deviation
Minimum Maximum Percentiles
25th 50th
(Median)
75th
jenis
komponen
21 3,57 1,720 1 7 2,00 4,00 4,00
Status PAP 21 1,43 ,507 1 2 1,00 1,00 2,00
103
Mann-Whitney Test
Ranks
Status PAP N Mean Rank Sum of Ranks
jenis komponen
Ya 12 14,38 172,50
Tidak 9 6,50 58,50
Total 21
Test Statisticsa
jenis komponen
Mann-Whitney U 13,500
Wilcoxon W 58,500
Z -3,059
Asymp. Sig. (2-tailed) ,002
Exact Sig. [2*(1-tailed Sig.)] ,002b
a. Grouping Variable: Status PAP
b. Not corrected for ties.
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Jenis kelamin * Status PAP 30 100,0% 0 0,0% 30 100,0%
Jenis kelamin * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Jenis kelamin
Laki-laki
Count 6 11 17
Expected Count 6,8 10,2 17,0
% within Status PAP 50,0% 61,1% 56,7%
% of Total 20,0% 36,7% 56,7%
Perempuan
Count 6 7 13
Expected Count 5,2 7,8 13,0
% within Status PAP 50,0% 38,9% 43,3%
% of Total 20,0% 23,3% 43,3%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
104
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Exact Sig. (2-
sided)
Exact Sig. (1-
sided)
Pearson Chi-Square ,362a 1 ,547
Continuity Correctionb ,051 1 ,821
Likelihood Ratio ,361 1 ,548
Fisher's Exact Test ,711 ,410
Linear-by-Linear Association ,350 1 ,554
N of Valid Cases 30
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,20.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Jenis kelamin
(Laki-laki / Perempuan)
,636 ,145 2,784
For cohort Status PAP = Ya ,765 ,320 1,828
For cohort Status PAP =
Tidak
1,202 ,651 2,220
N of Valid Cases 30
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Usia Ya 12 61,08 6,302 1,819
Tidak 18 57,89 7,722 1,820
Independent Samples Test
Levene's Test for
Equality of
Variances
t-test for Equality of Means
F Sig. t df Sig. (2-
tailed)
Mean
Differenc
e
Std.
Error
Differenc
e
95% Confidence
Interval of the
Difference
Lower Upper
Usia
Equal variances
assumed
1,788 ,192 1,191 28 ,244 3,194 2,683 -2,300 8,689
Equal variances
not assumed
1,241 26,72
0
,225 3,194 2,574 -2,089 8,477
105
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Status merokok * Status
PAP
30 100,0% 0 0,0% 30 100,0%
Status merokok * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Status merokok
Ya
Count 4 2 6
Expected Count 2,4 3,6 6,0
% within Status PAP 33,3% 11,1% 20,0%
% of Total 13,3% 6,7% 20,0%
pasif
Count 3 2 5
Expected Count 2,0 3,0 5,0
% within Status PAP 25,0% 11,1% 16,7%
% of Total 10,0% 6,7% 16,7%
mantan
Count 1 2 3
Expected Count 1,2 1,8 3,0
% within Status PAP 8,3% 11,1% 10,0%
% of Total 3,3% 6,7% 10,0%
tidak
Count 4 12 16
Expected Count 6,4 9,6 16,0
% within Status PAP 33,3% 66,7% 53,3%
% of Total 13,3% 40,0% 53,3%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 4,167a 3 ,244
Likelihood Ratio 4,199 3 ,241
Linear-by-Linear Association 3,902 1 ,048
N of Valid Cases 30
106
a. 6 cells (75,0%) have expected count less than 5. The minimum
expected count is 1,20.
Risk Estimate
Value
Odds Ratio for Status
merokok (Ya / pasif)
a
a. Risk Estimate statistics cannot be
computed. They are only computed for a
2*2 table without empty cells.
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%
Hipertensi * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Hipertensi
Ya
Count 9 4 13
Expected Count 5,2 7,8 13,0
% within Status PAP 75,0% 22,2% 43,3%
% of Total 30,0% 13,3% 43,3%
Tidak
Count 3 14 17
Expected Count 6,8 10,2 17,0
% within Status PAP 25,0% 77,8% 56,7%
% of Total 10,0% 46,7% 56,7%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
107
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Exact Sig. (2-
sided)
Exact Sig. (1-
sided)
Pearson Chi-Square 8,167a 1 ,004
Continuity Correctionb 6,160 1 ,013
Likelihood Ratio 8,488 1 ,004
Fisher's Exact Test ,008 ,006
Linear-by-Linear Association 7,895 1 ,005
N of Valid Cases 30
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,20.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Hipertensi
(Ya / Tidak)
10,500 1,889 58,359
For cohort Status PAP = Ya 3,923 1,320 11,656
For cohort Status PAP =
Tidak
,374 ,161 ,869
N of Valid Cases 30
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Penyakit atherosclerosis lain
* Status PAP
30 100,0% 0 0,0% 30 100,0%
Penyakit atherosclerosis lain * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Penyakit atherosclerosis lain
Ya
Count 4 3 7
Expected Count 2,8 4,2 7,0
% within Status PAP 33,3% 16,7% 23,3%
% of Total 13,3% 10,0% 23,3%
Tidak Count 8 15 23
Expected Count 9,2 13,8 23,0
108
% within Status PAP 66,7% 83,3% 76,7%
% of Total 26,7% 50,0% 76,7%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Exact Sig. (2-
sided)
Exact Sig. (1-
sided)
Pearson Chi-Square 1,118a 1 ,290
Continuity Correctionb ,380 1 ,537
Likelihood Ratio 1,100 1 ,294
Fisher's Exact Test ,392 ,266
Linear-by-Linear Association 1,081 1 ,299
N of Valid Cases 30
a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,80.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Penyakit
atherosclerosis lain (Ya /
Tidak)
2,500 ,445 14,037
For cohort Status PAP = Ya 1,643 ,701 3,849
For cohort Status PAP =
Tidak
,657 ,266 1,626
N of Valid Cases 30
Crosstabs
Minum obat * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Minum obat Teratur
Count 6 16 22
Expected Count 8,8 13,2 22,0
% within Status PAP 50,0% 88,9% 73,3%
% of Total 20,0% 53,3% 73,3%
Tidak teratur Count 6 2 8
109
Expected Count 3,2 4,8 8,0
% within Status PAP 50,0% 11,1% 26,7%
% of Total 20,0% 6,7% 26,7%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Exact Sig. (2-
sided)
Exact Sig. (1-
sided)
Pearson Chi-Square 5,568a 1 ,018
Continuity Correctionb 3,757 1 ,053
Likelihood Ratio 5,601 1 ,018
Fisher's Exact Test ,034 ,027
Linear-by-Linear Association 5,383 1 ,020
N of Valid Cases 30
a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 3,20.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Minum obat
(Teratur / Tidak teratur)
,125 ,020 ,799
For cohort Status PAP = Ya ,364 ,165 ,802
For cohort Status PAP =
Tidak
2,909 ,853 9,925
N of Valid Cases 30
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Obat dislipidemia * Status
PAP
30 100,0% 0 0,0% 30 100,0%
110
Obat dislipidemia * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Obat dislipidemia
ya
Count 5 3 8
Expected Count 3,2 4,8 8,0
% within Status PAP 41,7% 16,7% 26,7%
% of Total 16,7% 10,0% 26,7%
tidak
Count 7 8 15
Expected Count 6,0 9,0 15,0
% within Status PAP 58,3% 44,4% 50,0%
% of Total 23,3% 26,7% 50,0%
tidak minum obat
Count 0 7 7
Expected Count 2,8 4,2 7,0
% within Status PAP 0,0% 38,9% 23,3%
% of Total 0,0% 23,3% 23,3%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 6,632a 2 ,036
Likelihood Ratio 9,068 2 ,011
Linear-by-Linear Association 5,695 1 ,017
N of Valid Cases 30
a. 4 cells (66,7%) have expected count less than 5. The minimum
expected count is 2,80.
Risk Estimate
Value
Odds Ratio for Obat
dislipidemia (ya / tidak)
a
a. Risk Estimate statistics cannot be
computed. They are only computed for a
2*2 table without empty cells.
111
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
obat hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%
obat hipertensi * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
obat hipertensi
teratur
Count 5 2 7
Expected Count 2,8 4,2 7,0
% within Status PAP 41,7% 11,1% 23,3%
% of Total 16,7% 6,7% 23,3%
tidak teratur
Count 4 2 6
Expected Count 2,4 3,6 6,0
% within Status PAP 33,3% 11,1% 20,0%
% of Total 13,3% 6,7% 20,0%
tidak minum obat
Count 3 14 17
Expected Count 6,8 10,2 17,0
% within Status PAP 25,0% 77,8% 56,7%
% of Total 10,0% 46,7% 56,7%
Total
Count 12 18 30
Expected Count 12,0 18,0 30,0
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 8,198a 2 ,017
Likelihood Ratio 8,523 2 ,014
Linear-by-Linear Association 7,016 1 ,008
N of Valid Cases 30
a. 4 cells (66,7%) have expected count less than 5. The minimum
expected count is 2,40.
112
Risk Estimate
Value
Odds Ratio for obat
hipertensi (teratur / tidak
teratur)
a
a. Risk Estimate statistics cannot be
computed. They are only computed for a
2*2 table without empty cells.
Logistic Regression
Case Processing Summary
Unweighted Casesa N Percent
Selected Cases
Included in Analysis 30 100,0
Missing Cases 0 ,0
Total 30 100,0
Unselected Cases 0 ,0
Total 30 100,0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
Ya 0
Tidak 1
Categorical Variables Codings
Frequency Parameter coding
(1)
Minum obat Teratur 22 1,000
Tidak teratur 8 ,000
Hipertensi Ya 13 1,000
Tidak 17 ,000
Block 0: Beginning Block
Classification Tablea,b
Observed Predicted
Status PAP Percentage
Correct Ya Tidak
Step 0 Status PAP
Ya 0 12 ,0
Tidak 0 18 100,0
Overall Percentage 60,0
a. Constant is included in the model.
113
b. The cut value is ,500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant ,405 ,373 1,184 1 ,277 1,500
Variables not in the Equation
Score df Sig.
Step 0 Variables
Hipertensi(1) 8,167 1 ,004
obat_dm(1) 5,568 1 ,018
Overall Statistics 10,027 2 ,007
Block 1: Method = Backward Stepwise (Likelihood Ratio)
Omnibus Tests of Model Coefficients
Chi-square df Sig.
Step 1
Step 10,792 2 ,005
Block 10,792 2 ,005
Model 10,792 2 ,005
Step 2a
Step -2,303 1 ,129
Block 8,488 1 ,004
Model 8,488 1 ,004
a. A negative Chi-squares value indicates that the Chi-squares
value has decreased from the previous step.
Model Summary
Step -2 Log likelihood Cox & Snell R
Square
Nagelkerke R
Square
1 29,589a ,302 ,408
2 31,892a ,246 ,333
a. Estimation terminated at iteration number 4 because parameter
estimates changed by less than ,001.
Hosmer and Lemeshow Test
Step Chi-square df Sig.
1 ,070 2 ,966
2 ,000 0 .
114
Contingency Table for Hosmer and Lemeshow Test
Status PAP = Ya Status PAP = Tidak Total
Observed Expected Observed Expected
Step 1
1 5 5,124 1 ,876 6
2 4 3,876 3 3,124 7
3 1 ,876 1 1,124 2
4 2 2,124 13 12,876 15
Step 2 1 9 9,000 4 4,000 13
2 3 3,000 14 14,000 17
Classification Tablea
Observed Predicted
Status PAP Percentage
Correct Ya Tidak
Step 1 Status PAP
Ya 9 3 75,0
Tidak 4 14 77,8
Overall Percentage 76,7
Step 2 Status PAP
Ya 9 3 75,0
Tidak 4 14 77,8
Overall Percentage 76,7
a. The cut value is ,500
Variables in the Equation
B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B)
Lower Upper
Step 1a
Hipertensi(1) -2,017 ,919 4,820 1 ,028 ,133 ,022 ,805
obat_dm(1) 1,552 1,048 2,190 1 ,139 4,719 ,604 36,836
Constant ,250 1,055 ,056 1 ,813 1,284
Step 2a
Hipertensi(1) -2,351 ,875 7,219 1 ,007 ,095 ,017 ,529
Constant 1,540 ,636 5,863 1 ,015 4,667
a. Variable(s) entered on step 1: Hipertensi, obat_dm.
115
Model if Term Removed
Variable Model Log
Likelihood
Change in -2 Log
Likelihood
df Sig. of the
Change
Step 1 Hipertensi -17,390 5,190 1 ,023
obat_dm -15,946 2,303 1 ,129
Step 2 Hipertensi -20,190 8,488 1 ,004
Variables not in the Equation
Score df Sig.
Step 2a
Variables obat_dm(1) 2,360 1 ,124
Overall Statistics 2,360 1 ,124
a. Variable(s) removed on step 2: obat_dm.
top related